Staedtler F, Pospiech A, Steiner S, Looser M
Novartis Pharma AG, Preclinical Safety-Toxicology/Pathology, Basel, Switzerland.
Mol Biotechnol. 1998 Dec;10(3):269-72. doi: 10.1007/BF02740848.
DNA sequencing templates of individual point mutants of the lacI target gene were amplified by polymerase chain reaction (PCR). By mixing the PCR fragments from two individual mutants in a defined ratio, samples of artificial heterozygous composition were prepared. These samples were then submitted to automated DNA sequencing. The simultaneous, visual comparison of the mixed mutant traces using a graphics program efficiently revealed all heterozygous positions. Based on the individual intensities of the heterozygous base signals the identified point mutations could be assigned to the corresponding mutants. This efficient approach doubles the sample throughput for both the sequencing reactions and the gel electrophoresis using an automated DNA sequencing system.
通过聚合酶链反应(PCR)扩增乳糖抑制蛋白(lacI)靶基因各个点突变体的DNA测序模板。以确定的比例混合来自两个个体突变体的PCR片段,制备人工杂合组成的样本。然后将这些样本进行自动DNA测序。使用图形程序对混合突变体序列进行同步可视化比较,能有效地揭示所有杂合位点。根据杂合碱基信号的个体强度,可以将鉴定出的点突变分配给相应的突变体。这种高效的方法使用自动DNA测序系统,使测序反应和凝胶电泳的样本通量提高了一倍。